Soticlestat, formerly known as TAK-935/OV935, is an investigational drug developed by Takeda Pharmaceuticals. It is a highly selective, potent inhibitor of the enzyme cholesterol 24-hydroxylase, which plays a crucial role in the regulation of neurosteroid synthesis. Neurosteroids are naturally occurring molecules in the brain that modulate neuronal activity, including in epilepsy. Our recent study adds Read More…